Artesian

Artesian is the Sydney-based global alternative manager that has quietly built one of Australia’s most active early-stage venture portfolios, with roughly 625 startups in its books across thematic strategies in climate, agrifood, health, AI and robotics, education, and gender equality. The firm invests across Australia, China, Indonesia, Singapore, the United States, and the United Kingdom, and its model is closer to a thematic platform than to a traditional concentrated venture fund. Artesian is not a healthcare specialist, and health is one strategy among many; for founders raising in the Asia-Pacific region or building companies with mission-aligned healthcare exposure, Artesian is a useful early-stage partner with a global footprint.

The thesis is thematic and breadth-oriented: Artesian runs vehicles aligned to specific impact and innovation themes, and within healthcare the firm is active in digital health, medical devices and MedTech, and AI and machine learning in healthcare. The firm’s investment criteria emphasize scalability and mission alignment, and the firm is structurally a co-investor rather than a typical lead. Co-investment posture means Artesian is most useful alongside a credible lead investor who anchors the round on terms and governance, with Artesian providing additional capital, geographic reach, and thematic alignment. Founders should expect a partner whose questions focus on scalability, market geography, and thesis fit rather than on deep operational engagement.

The portfolio reflects the breadth of the platform. Named investments include PlasmaLeap, CLIQ, Ferronova, Squarespace, and VideoVerse, spanning healthcare, technology, and consumer categories. Within healthcare specifically, Artesian has been active in Australian medical device and digital health companies, and the firm’s geographic spread allows it to participate in cross-border rounds when an Asia-Pacific company is expanding into Western markets or vice versa. The pattern across the portfolio is a willingness to take small early positions across a wide universe of companies and to compound exposure over time as themes mature.

Check sizes are in the $250,000 to $1 million range at Pre-Seed, Seed, and Series A, consistent with a thematic platform that takes many small early positions rather than concentrated lead investments. The capital stack positioning is co-investor and follow-on participant rather than round anchor. Founders raising a $2 million to $4 million seed will find Artesian a credible co-investor who can bring geographic reach, particularly into the Asia-Pacific region. Founders raising larger rounds will typically include Artesian as a partial check alongside a larger lead. The firm’s reserves are scaled across themes, which means follow-on capital is selectively deployed.

The team is led by co-founders Jeremy Colless, Matthew Clunies-Ross, and John McCartney, who have built the platform across multiple geographies and thematic strategies. Decision-making is investment-committee-driven within each thematic vehicle, and the firm’s communication style reflects its global, thematic posture: meetings tend to focus on thesis fit, geography, and mission alignment, with operational and clinical depth handled at the lead-investor level. Founders should expect thoughtful, thesis-aware diligence rather than a deep operational deep-dive.

The most reliable path into Artesian is a warm introduction from a portfolio founder, a thematic accelerator partner in the firm’s network, or a co-investor who has previously syndicated with the firm. Introductions from Australian and Asia-Pacific innovation ecosystems are particularly effective, as are connections through universities and research institutions in the firm’s geography. Cold outreach is read when it fits a thematic strategy and when there is a credible lead investor signal. Communication after first contact tends to be fast when the thesis fits and clear when it does not.

Approach Artesian when you are raising a Pre-Seed, Seed, or Series A round in a thematic area like health, AI, or medical devices, when you have a credible lead investor anchoring the round, and when geographic reach into the Asia-Pacific region adds value. Do not approach when you need a lead investor with deep healthcare operating depth, when you are raising a larger Series B or growth round, or when you need a partner with concentrated commercial healthcare expertise. Artesian is a global thematic platform that works best as a co-investor for mission-aligned healthcare founders raising early rounds with geographic optionality.